Natco Pharma Ltd 14 Nov 2026 12:00 AM
Natco Pharma Ltd consolidated sales up 31.57% on year in Q2FY2027, net profit jumped 41.90%,
Natco Pharma Ltd share price ticked higher by 0.43% to Rs 812.25 after the company`s net profit saw a strong growth of 41.90% to Rs 173.4 crore, while revenue from operations increased sharply by 31.57% to Rs 967.3 crore in Q2FY27 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.83 lakh crore, rising 6.82%. It has marginally improved by 2.52% over last one week and moved up slightly by 5.98% in last one month while the market capitalization of Natco Pharma Ltd has improved by 0.63% and 1.42% in the same period respectively. Profit before tax (PBT) of Natco Pharma Ltd stood at Rs 243.2 crore in Q2 FY27, crashing by 60.37% year-on-year, and jumping 31.03% quarter-on-quarter. EBITDA came in at Rs 206 crore, tanking 57.05% YoY and surging by 61.67% sequentially. Total expenses surged 27.32% to Rs 758.6 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 171.7 crore, growing marginally by 8.81% YoY, while employee benefits expense was at Rs 203.6 crore, surging 13.55% YoY. For FY26, revenue from operations declined slightly by 7.93% to Rs 4078.3 crore, while net profit tanked by 27.16% to Rs 1371.9 crore, compared to previous FY. EBITDA soared by 181190% to Rs 1138.9 crore, and PBT collapsed by 34.94% to Rs 1490.8 crore compared to previous FY. The company`s consolidated net cash flow from operating activities stood at Rs 1768.3 crore in FY26, as against Rs 1696.8 crore in FY25. Natco Pharma Ltd slipped 0.87% in last one year, outperforming the benchmark BSE Sensex which has softened by 3.42% during the same period.
Natco Pharma Ltd 13 Nov 2026 12:00 AM
Natco Pharma Ltd consolidated sales up 31.57% on year in Q2FY2027, net profit surged by 41.90%,
Natco Pharma Ltd share price ticked higher by 0.02% to Rs 808.8 after the company`s net profit soared by 41.90% to Rs 173.4 crore, while revenue from operations increased sharply by 31.57% to Rs 967.3 crore in Q2FY27 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.83 lakh crore, rising 6.59%. It has improved by 2.89% over last one week and ticked higher by 6.37% in last one month while the market capitalization of Natco Pharma Ltd has marginally improved by 0.20% and 1.84% in the same period respectively. Profit before tax (PBT) of Natco Pharma Ltd stood at Rs 243.2 crore in Q2 FY27, plunging by 60.37% year-on-year, and jumping 31.03% quarter-on-quarter. EBITDA came in at Rs 206 crore, crashing by 57.05% YoY and rallying 61.67% sequentially. Total expenses jumped by 27.32% to Rs 758.6 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 171.7 crore, growing marginally by 8.81% YoY, while employee benefits expense was at Rs 203.6 crore, soaring 13.55% YoY. For FY26, revenue from operations declined slightly by 7.93% to Rs 4078.3 crore, while net profit tanked by 27.16% to Rs 1371.9 crore, compared to previous FY. EBITDA witnessed a strong improvement of 181190% to Rs 1138.9 crore, and PBT plunged by 34.94% to Rs 1490.8 crore compared to previous FY. The company`s consolidated net cash flow from operating activities stood at Rs 1768.3 crore in FY26, as against Rs 1696.8 crore in FY25. Natco Pharma Ltd declined by 0.95% in last one year, outperforming the benchmark BSE Sensex which has slipped by 3.03% during the same period.
Natco Pharma Ltd 13 Nov 2026 12:00 AM
Natco Pharma announces a second interim dividend of Rs 1.25 per equity share for FY27,
Natco Pharma Limited declared a second interim dividend of Rs 1.25 (62.50%) per equity share of Rs 2 each for the financial year 2026-27, with November 19, 2026, set as the record date, and payment commencing on November 27, 2026.
Natco Pharma Ltd 29 Oct 2026 12:00 AM
Natco Pharma to review financial results and potential dividend at November board meeting,
Natco Pharma Limited will hold a board meeting on November 13, 2026, to consider the unaudited financial results for the quarter and half year ended September 30, 2026, and to consider the declaration of a second interim dividend for the financial year ending 2026-27. The company also announced that the trading window for its directors, designated persons, and connected persons was closed from October 30, 2026, and will reopen on November 16, 2026, in accordance with SEBI regulations.
Natco Pharma Ltd 16 Oct 2026 12:00 AM
Natco Pharma reported securities dematerialization details to BSE and NSE for Q3 2026,
Natco Pharma Limited submitted a certificate to the BSE Ltd and National Stock Exchange of India Ltd under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, confirming that securities received for dematerialization have been mutilated and cancelled and the details of securities were furnished to the stock exchanges, with Venture Capital and Corporate Investments Private Limited acting as the authorized signatory.
Subscribe for our
newsletter
Open Account Now